At the time of writing, Mereo Biopharma Group Plc ADR [MREO] stock is trading at $2.62, up 4.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MREO shares have gain 5.22% over the last week, with a monthly amount drifted -9.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mereo Biopharma Group Plc ADR [NASDAQ: MREO] stock has seen the most recent analyst activity on December 06, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $7. Previously, Robert W. Baird started tracking the stock with Outperform rating on June 13, 2024, and set its price target to $8. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $4 on August 12, 2022. BTIG Research initiated its recommendation with a Buy and recommended $10 as its price target on May 05, 2021. Needham started tracking with a Buy rating for this stock on April 05, 2021, and assigned it a price target of $10.
For the past year, the stock price of Mereo Biopharma Group Plc ADR fluctuated between $2.25 and $5.02. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. Mereo Biopharma Group Plc ADR [NASDAQ: MREO] shares were valued at $2.62 at the most recent close of the market. An investor can expect a potential return of 157.63% based on the average MREO price forecast.
Analyzing the MREO fundamentals
Gross Profit Margin for this corporation currently stands at -1.07% with Operating Profit Margin at -104.62%, Pretax Profit Margin comes in at -116.34%, and Net Profit Margin reading is -117.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.69 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.53 points at the first support level, and at 2.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.68, and for the 2nd resistance point, it is at 2.75.
Ratios To Look Out For
It is important to note that Mereo Biopharma Group Plc ADR [NASDAQ:MREO] has a current ratio of 6.10. Also, the Quick Ratio is 6.10, while the Cash Ratio stands at 5.67.
Transactions by insiders
Recent insider trading involved Scots-Knight Denise, Chief Executive Officer, that happened on Sep 13 ’24 when 60046.0 shares were sold. Chief Executive Officer, Scots-Knight Denise completed a deal on Sep 12 ’24 to sell 28611.0 shares. Meanwhile, Chief Scientific Officer Lewicki John A. sold 10937.0 shares on Sep 13 ’24.
